secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-134936
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q4 net gain $2.2M; annual loss narrows; HCW9302 Phase 1 underway
------------------------------------------------------------------------------

- Q4 2025 net gain of $2.2M vs $3.4M loss in Q4 2024; FY 2025 net loss narrowed to $6.5M from $30.0M.
- Q4 revenue $27K vs $395K year ago due to Wugen license suspension; FY revenue $54K vs $2.6M.
- Initiated Phase 1 trial of HCW9302 for alopecia areata in Nov 2025; preliminary data expected H1 2026.
- Received $3.5M upfront fee ($2.9M net) from Trimmune for worldwide license of HCW11-006; eligible for milestones and royalties.
- Going concern doubt remains; Nasdaq issued bid price deficiency notice on March 26, 2026 after regaining compliance in Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526134936/0001193125-26-134936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526134936/hcwb-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-134936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer